DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with ...

Scientists tested a wearable blood sugar monitor on adults who weren't taking insulin. The results revealed a measurable ...

(This is an excerpt of Health Rounds, winner of the 2026 Publishers Newsletter Award for Best Science Newsletter, where we ...

Continuous glucose monitors can dramatically improve blood sugar control among people with type 2 diabetes who aren’t yet ...

The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare ...

The benefits of wearable continuous glucose monitoring devices extend even to patients with diabetes who do not use insulin, ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

DexCom (DXCM) stock jumps as peer-reviewed data from a study for the G7 insulin pump in type 2 diabetes boost its Medicare coverage hopes.

At 26 weeks, 68% of Dexcom G7 users had A1C below 7.5%, while 46% were below 7.0%; 97% still used CGM, most daily. The trial was published in NEJM.

DexCom, Inc. announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the ...